Cara Therapeutics reported $27.48M in Operating Expenses for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Operating Expenses Change
Acadia Pharmaceuticals ACAD:US $ 168.21M 60.27M
Acelrx Pharmaceuticals ACRX:US $ 14.14M 4.71M
Aerie Pharmaceuticals AERI:US $ 51.45M 12.03M
Cara Therapeutics CARA:US $ 27.48M 5.23M
Chugai Pharma 4519:JP 135.67B 37.88B
Depomed DEPO:US $ 24.34M 639K
Halozyme Therapeutics HALO:US $ 118.3M 76.7M
Horizon Pharma HZNP:US $ 787.85M 96.93M
JAZZ PHA JAZZ:US $ 847.33M 121.16M
Johnson & Johnson JNJ:US $ 18.18B 616M
Neurocrine Biosciences NBIX:US $ 393.5M 86M
Pacira Pharmaceuticals PCRX:US $ 138.18M 2.42M
Pain Therapeutics PTIE:US $ 19.92M 2.1M
Pfizer PFE:US $ 15640M 148M
Redhill Biopharma RDHL:US 31.47M 11.3M
Revance Therapeutics RVNC:US $ 86.21M 1.27M
Supernus Pharmaceuticals SUPN:US $ 158.7M 8.17M
Teva Pharmaceutical Industries TEVA:US 4.74B 361M
Vanda Pharmaceuticals VNDA:US $ 60.93M 6.93M